Frenova Renal Research Announces Expansion of F1RST Up™ (Frenova Rapid STart Up) Alliance of Investigative Sites Designed t...
June 20 2017 - 9:30AM
Business Wire
Membership Climbs to 55 Renal Investigators
Representing 23 Research Sites
Frenova Renal Research, the world’s only drug and medical device
contract clinical development services provider dedicated
exclusively to renal research, today announced that its F1RST Up™
alliance of clinical research sites focusing on kidney disease has
expanded to include 55 physician investigators representing 23
sites.
“The success of F1RST Up is clear evidence of the value the
alliance provides to our sponsor clients, our alliance partners and
to other contract research organizations (CROs) we collaborate
with,” said Kurt Mussina, general manager of Frenova. “F1RST Up
accelerates study startup by taking a no-nonsense approach to
driving low-value administrative and contracting burdens out of the
startup process. This provides our partners and customers with a
better startup experience, equating to much better value.”
The F1RST Up alliance membership includes nephrology practices
caring for large numbers of chronic kidney disease (CKD) patients,
including end stage renal disease (ESRD) patients. F1RST Up
investigators are highly experienced clinical researchers in renal
disease and its adjacencies, including vascular access and care,
cardio-renal conditions, rare diseases, infectious diseases and
transplant. The alliance leverages Frenova’s access to proprietary
clinical research assets to inform protocol design and to carry out
highly targeted and efficient patient recruitment efforts.
“We formed this alliance with the leading physician
investigators from across Frenova’s network of 260 clinical
research sites,” said Christina Kahn, Frenova’s F1RST Up alliance
lead. “This is important because it means F1RST Up offers sponsors
access to a uniquely concentrated source of both high quality renal
research sites and a substantial number of patients.”
To learn more about Frenova F1RST Up, visit
FrenovaRenalResearch.com/F1RST-Up.
About Frenova Renal Research
Frenova is the world’s only drug and medical device contract
clinical development services provider dedicated exclusively to
renal research. As a Fresenius Medical Care North America company,
Frenova manages a networked system of clinical research assets and
resources including over 450 principal investigators at more than
260 sites representing 160 medical practices. Frenova manages
clinical trials in kidney disease and its adjacent medical
conditions. When you need to conduct a complete renal clinical
program, trust the partner that’s completely renal — Frenova Renal
Research. Visit www.FrenovaRenalResearch.com for more
information.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170620005959/en/
SCORR MarketingLea Studer,
308-237-5567lea@scorrmarketing.com
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Apr 2023 to Apr 2024